Table 1 Patient characteristics
CAB with GnRH antagonist | CAB with GnRH agonist | |||
|---|---|---|---|---|
n = 34 | n = 50 | P-value | ||
Median age at diagnosis years (range) | 75(50–88) | 74 (55–85) | 0.09† | |
≥ 75 years old (%) | 19 (56) | 22 (44) | 0.28‡ | |
Median pretreatment PSA level ng/mL (range) | 176.4 (51.5–5076) | 136.4 (51.9–5827) | 0.82† | |
Pathological diagnosis | Gleason score 6 | 1 | 2 | 0.78‡ |
Gleason score 7 | 9 | 8 | ||
Gleason score 8 | 11 | 21 | ||
Gleason score 9 | 11 | 16 | ||
Gleason score10 | 2 | 3 | ||
No of Gleason score 8–10 (%) | 24(70) | 40(80) | 0.19‡ | |
T category | T2 | 4 | 9 | 0.60‡ |
T3 | 24 | 33 | ||
T4 | 6 | 7 | ||
Unknown | 0 | 1 | ||
Bone metastasis | EOD0 | 16 | 22 | 0.72‡ |
EOD1 | 7 | 9 | ||
EOD2 | 8 | 10 | ||
EOD3 | 3 | 6 | ||
EOD4 | 0 | 1 | ||
Unknown | 0 | 2 | ||
Lymph node metastasis (%) | Positive | 21 (62) | 25 (50) | 0.58‡ |
Negative | 13 (38) | 23 (46) | ||
Unknown | 0 | 2 | ||
When to use bicalutamide | Concurrently | 15 | 12 | |
Before | 19 | 38 | ||
Median observation period days (range) | 761 (212–1529) | 1141(175–3419) | < 0.01* | |